# A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer

Source: https://onco.cc/trials/nct06527300/  
OnCo record `nct06527300` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of NHWD-870 run by Zhejiang Wenda Pharma Technology LTD., of unknown status on the registry.

## Summary

A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer is a phase 2 interventional study registered as NCT06527300 by Zhejiang Wenda Pharma Technology LTD., with 48 participants planned, started 2024-04-25. Conditions recorded: Advanced Solid Tumor (Phase 1). Interventions recorded: NHWD-870 HCl.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06527300
- Phase: 2
- Setting: A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
- Sponsor: Zhejiang Wenda Pharma Technology LTD.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT06527300: https://clinicaltrials.gov/study/NCT06527300

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [NHWD-870](https://onco.cc/drugs/nhwd-870/)
- companies: [Zhejiang Wenda Pharma](https://onco.cc/companies/zhejiang-wenda-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06527300.json